Show simple item record

dc.contributor.authorGrealy, Rebeccaen_US
dc.contributor.authorGriffiths, Lynen_US
dc.date.accessioned2017-04-24T09:14:08Z
dc.date.available2017-04-24T09:14:08Z
dc.date.issued2009en_US
dc.date.modified2010-05-19T06:30:21Z
dc.identifier.issn11771062en_US
dc.identifier.doihttp://adisonline.com/moleculardiagnosistherapy/Abstract/2009/13020/Current_Status_of_Pharmacogenomics_Testing_for.1.aspxen_AU
dc.identifier.urihttp://hdl.handle.net/10072/29754
dc.description.abstractSkin cancer is one of the most commonly occurring cancer types, with substantial social, physical, and financial burdens on both individuals and societies. Although the role of UV light in initiating skin cancer development has been well characterized, genetic studies continue to show that predisposing factors can influence an individual's susceptibility to skin cancer and response to treatment. In the future, it is hoped that genetic profiles, comprising a number of genetic markers collectively involved in skin cancer susceptibility and response to treatment or prognosis, will aid in more accurately informing practitioners' choices of treatment. Individualized treatment based on these profiles has the potential to increase the efficacy of treatments, saving both time and money for the patient by avoiding the need for extensive or repeated treatment. Increased treatment responses may in turn prevent recurrence of skin cancers, reducing the burden of this disease on society. Currently existing pharmacogenomic tests, such as those that assess variation in the metabolism of the anticancer drug fluorouracil, have the potential to reduce the toxic effects of anti-tumor drugs used in the treatment of non-melanoma skin cancer (NMSC) by determining individualized appropriate dosage. If the savings generated by reducing adverse events negate the costs of developing these tests, pharmacogenomic testing may increasingly inform personalized NMSC treatment.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_AU
dc.languageEnglishen_US
dc.language.isoen_AU
dc.publisherADIS International Ltd.en_US
dc.publisher.placeNew Zealanden_US
dc.publisher.urihttp://adisonline.com/moleculardiagnosistherapy/Pages/default.aspxen_AU
dc.relation.ispartofstudentpublicationYen_AU
dc.relation.ispartofpagefrom65en_US
dc.relation.ispartofpageto72en_US
dc.relation.ispartofissue2en_US
dc.relation.ispartofjournalMolecular Diagnosis and Therapyen_US
dc.relation.ispartofvolume13en_US
dc.rights.retentionYen_AU
dc.subject.fieldofresearchGenomicsen_US
dc.subject.fieldofresearchcode060408en_US
dc.titleCurrent status of pharmacogenomics testing for anti-tumour drug therapies: approaches to non-melanoma skin canceren_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.facultyGriffith Health, School of Medicineen_US
gro.rights.copyrightCopyright 2009 Adis Data Information BV. Self-archiving of the author-manuscript version is not yet supported by this publisher. Please refer to the journal link for access to the definitive, published version or contact the author[s] for more information.en_AU
gro.date.issued2009
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record